ArticleDiscover oncology2025
Exploring novel biomarkers and immunotherapeutic targets for biofeedback therapies to reveal the tumor-associated immune microenvironment through a multimetric analysis of kidney renal clear cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundKidney renal clear cell carcinoma (KIRC) constitutes the primary subtype of renal cell carcinoma, representing 75% to 80% of cases and carrying a substantial cancer-specific mortality rate of up to 24%. Despite advancements in treatment options, KIRC displays notable resistance to conventional therapies, emphasizing the need for innovative targeted immunotherapeutic strategies. Chromatin regulators (CRs), pivotal proteins controlling gene expression and critical biological processes, play a crucial role in the initiation and progression of KIRC. This study employed a multi-omics approach to evaluate the impact of CR-associated genes on KIRC prognosis.
methodsThe study utilized the TCGA-KIRC dataset and employed LASSO Cox regression to construct and validate a prognostic model that focuses on genes influencing KIRC prognosis. The research investigated interactions among gene characteristics, clinical parameters, the tumor microenvironment, targeted immunotherapy, and drug responsiveness. Experimental validation, encompassing various techniques such as cell culture, transient transfection, qPCR, Transwell assays, confirmed the robust predictive capability of the BRD9 gene.
resultsThe analysis identified the risk score of CRs as an independent factor determining KIRC prognosis. Furthermore, the study introduced a predictive Nomogram model that integrates clinical attributes and risk assessment. Significantly, BRD9 exhibited substantially elevated expression within KIRC cells, underscoring its role in driving cancer cell proliferation, invasion, and migration. These findings suggest the potential for tailored immunotherapy targeting BRD9 in the treatment of KIRC.
conclusionThis study presents an innovative prognostic framework for KIRC based on multi-omics approaches, seamlessly incorporating CRs. This model holds promise for improving the accuracy of prognosis prediction for KIRC patients, laying a robust foundation for the development of targeted immunotherapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.